2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses trials investigating immunotherapy in kidney cancer.
Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice-president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses trials investigating immunotherapy in kidney cancer.
There are ongoing trials investigating immunotherapy regimens in patients with kidney cancer. The PROSPER trial is investigating a neoadjuvant therapy followed by an adjuvant therapy, whereas a different trial is only investigating adjuvant therapy, states Uzzo.
Currently, there is not a lot of adjuvant therapy being given in the kidney cancer space, which might affect how the trials accrue patients, explains Uzzo.